COMMENTARY ON THE LAW
Ovarian cancer – from biology to clinic
Katarzyna Aleksandra Kujawa 1 , Katarzyna Marta Lisowska 11. Centrum Badań Translacyjnych i Biologii Molekularnej Nowotworów, Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Oddział Gliwice
Published: 2015-12-02
DOI: 10.5604/17322693.1184451
GICID: 01.3001.0009.6599
Available language versions: en pl
Issue: Postepy Hig Med Dosw 2015; 69 : 1275-1290
Abstract
Ovarian cancer is the most frequent cause of deaths from among gynecologic malignancies. Due to its asymptomatic development the disease is frequently diagnosed at an advanced, incurable stages. Although ovarian cancers usually respond well to the first line chemotherapy based on platinum compounds and taxanes, majority of patients develop recurrence and chemo-resistance. Despite many years of studies there is still lack of reliable diagnostic markers as well as other diagnostic methods enabling early detection and suitable for screening. Thus, current studies are aimed on finding new biomarkers with diagnostic, prognostic and predictive potential as well as on the search for the new therapeutic targets.Interestingly, an understanding of ovarian cancer etiology has changed fundamentally within recent years. The classical theory, claiming that ovarian cancers originate from ovarian surface epithelial cells, was undermined. Currently, there is a lot of evidence that majority of serous ovarian cancers have its origin in malignant tubal epithelium, while endometrioid and clear cell ovarian cancers develop most likely from endometriosis.These new findings will have an impact on diagnostic approaches as well as on the prevention options for women with genetic predisposition to ovarian cancer. The new knowledge about an origin of different histological types of ovarian cancer may open new pathways in basic research and clinical studies. In this paper we report current knowledge about ovarian cancer risk factors, we also present the arguments for extraovarian origin of the majority of ovarian cancers and stress the mechanisms of action of new drugs for targeted therapies that show most promising results in the current clinical trials.
References
- 1. Anglesio M.S., Kommoss S., Tolcher M.C., Clarke B., Galletta L.,Porter H., Damaraju S., Fereday S., Winterhoff B.J., Kalloger S.E.,Senz J., Yang W., Steed H., Allo G., Ferguson S. i wsp.: Molecularcharacterization of mucinous ovarian tumours supports a stratifiedtreatment approach with HER2 targeting in 19% of carcinomas. J.Pathol., 2013; 229: 111-120
Google Scholar - 1. Anglesio M.S., Kommoss S., Tolcher M.C., Clarke B., Galletta L.,Porter H., Damaraju S., Fereday S., Winterhoff B.J., Kalloger S.E.,Senz J., Yang W., Steed H., Allo G., Ferguson S. i wsp.: Molecularcharacterization of mucinous ovarian tumours supports a stratifiedtreatment approach with HER2 targeting in 19% of carcinomas. J.Pathol., 2013; 229: 111-120
Google Scholar - 2. Auersperg N.: Ovarian surface epithelium as a source of ovarian cancers:unwarranted speculation or evidence-based hypothesis? Gynecol.Oncol., 2013; 130: 246-251
Google Scholar - 2. Auersperg N.: Ovarian surface epithelium as a source of ovarian cancers:unwarranted speculation or evidence-based hypothesis? Gynecol.Oncol., 2013; 130: 246-251
Google Scholar - 3. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C.: Ovariansurface epithelium: biology, endocrinology, and pathology. Endocr.Rev., 2001; 22: 255-288
Google Scholar - 3. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C.: Ovariansurface epithelium: biology, endocrinology, and pathology. Endocr.Rev., 2001; 22: 255-288
Google Scholar - 4. Bartel H.T.: Układ moczowo-płciowy. W: Embriologia Medyczna.Wyd. I. red.: Bartel H.T. Wydawnictwo Lekarskie PZWL, Warszawa2008, 142-146
Google Scholar - 4. Bartel H.T.: Układ moczowo-płciowy. W: Embriologia Medyczna.Wyd. I. red.: Bartel H.T. Wydawnictwo Lekarskie PZWL, Warszawa2008, 142-146
Google Scholar - 5. Callahan M.J., Crum C.P., Medeiros F., Kindelberger D.W., Elvin J.A.,Garber J.E., Feltmate C.M., Berkowitz R.S., Muto M.G.: Primary fallopian tube malignancies in BRCA-positive women undergoing surgeryfor ovarian cancer risk reduction. J. Clin. Oncol., 2007; 25: 3985-3990
Google Scholar - 5. Callahan M.J., Crum C.P., Medeiros F., Kindelberger D.W., Elvin J.A.,Garber J.E., Feltmate C.M., Berkowitz R.S., Muto M.G.: Primary fallopian tube malignancies in BRCA-positive women undergoing surgeryfor ovarian cancer risk reduction. J. Clin. Oncol., 2007; 25: 3985-3990
Google Scholar - 6. Campbell I.G., Russel S.E., Choong D.Y., Montgomery K.G., CiavarellaM.L., Hooi C.S., Cristiano B.E., Pearson R.B., Phillips W.A.:Mutation of the PIK3CA gene in ovarian and breast cancer. CancerRes., 2004; 64: 7678-7681
Google Scholar - 6. Campbell I.G., Russel S.E., Choong D.Y., Montgomery K.G., CiavarellaM.L., Hooi C.S., Cristiano B.E., Pearson R.B., Phillips W.A.:Mutation of the PIK3CA gene in ovarian and breast cancer. CancerRes., 2004; 64: 7678-7681
Google Scholar - 7. Chan A., Gilks B., Kwon J., Tinker A.V.: New insights into thepathogenesis of ovarian carcinoma: time to rethink ovarian cancerscreening. Obstet. Gynecol., 2012; 120: 935-940
Google Scholar - 7. Chan A., Gilks B., Kwon J., Tinker A.V.: New insights into thepathogenesis of ovarian carcinoma: time to rethink ovarian cancerscreening. Obstet. Gynecol., 2012; 120: 935-940
Google Scholar - 8. Choi K.C., Kang S.K., Tai C.J., Auersperg N., Leung P.C.: Folliclestimulatinghormone activates mitogen-activated protein kinase inpreneoplastic and neoplastic ovarian surface epithelial cells. J. Clin.Endocrinol. Metab., 2002; 87: 2245-2253
Google Scholar - 8. Choi K.C., Kang S.K., Tai C.J., Auersperg N., Leung P.C.: Folliclestimulatinghormone activates mitogen-activated protein kinase inpreneoplastic and neoplastic ovarian surface epithelial cells. J. Clin.Endocrinol. Metab., 2002; 87: 2245-2253
Google Scholar - 9. ClinicalTrials.gov https://clinicaltrials.gov (02.02.2015)
Google Scholar - 9. ClinicalTrials.gov https://clinicaltrials.gov (02.02.2015)
Google Scholar - 10. ClinicalTrials.gov. Efficacy and Safety of MORAb-003 in SubjectsWith Platinum-sensitive Ovarian Cancer in First Relapse(NCT00849667) https://www.clinicaltrials.gov/ct2/results?term=NCT00849667&Search=Search (23.08.2014)
Google Scholar - 10. ClinicalTrials.gov. Efficacy and Safety of MORAb-003 in SubjectsWith Platinum-sensitive Ovarian Cancer in First Relapse(NCT00849667) https://www.clinicaltrials.gov/ct2/results?term=NCT00849667&Search=Search (23.08.2014)
Google Scholar - 11. ClinicalTrials.gov. Study for Women With Platinum ResistantOvarian Cancer Evaluating EC145 in Combination With Doxil®(NCT01170650) https://www.clinicaltrials.gov/ct2/results?term=NCT01170650&Search=Search (02.02.2015)
Google Scholar - 11. ClinicalTrials.gov. Study for Women With Platinum ResistantOvarian Cancer Evaluating EC145 in Combination With Doxil®(NCT01170650) https://www.clinicaltrials.gov/ct2/results?term=NCT01170650&Search=Search (02.02.2015)
Google Scholar - 12. Colombo N., Mangili G., Mammoliti S., Kalling M., Tholander B.,Sternas L., Buzenet G., Chamberlain D.: A phase II study of afliberceptin patients with advanced epithelial ovarian cancer and symptomaticmalignant ascites. Gynecol. Oncol., 2012; 125: 42-47
Google Scholar - 12. Colombo N., Mangili G., Mammoliti S., Kalling M., Tholander B.,Sternas L., Buzenet G., Chamberlain D.: A phase II study of afliberceptin patients with advanced epithelial ovarian cancer and symptomaticmalignant ascites. Gynecol. Oncol., 2012; 125: 42-47
Google Scholar - 13. Dehari R., Kurman R.J., Logani S., Shih I.M.: The developmentof high-grade serous carcinoma from atypical proliferative (borderline)serous tumors and low-grade micropapillary serous carcinoma:a morphologic and molecular genetic analysis. Am. J. Surg. Pathol.,2007; 31: 1007-1012
Google Scholar - 13. Dehari R., Kurman R.J., Logani S., Shih I.M.: The developmentof high-grade serous carcinoma from atypical proliferative (borderline)serous tumors and low-grade micropapillary serous carcinoma:a morphologic and molecular genetic analysis. Am. J. Surg. Pathol.,2007; 31: 1007-1012
Google Scholar - 14. Demetriou C.A., Chen J., Polidoro S., van Veldhoven K., CueninC., Campanella G., Brennan K., Clavel-Chapelon F., Dossus L., KvaskoffM., Drogan D., Boeing H., Kaaks R., Risch A., Trichopoulos D. i wsp.:Methylome analysis and epigenetic changes associated with menarchealage. PLoS One, 2013; 8: e79391
Google Scholar - 14. Demetriou C.A., Chen J., Polidoro S., van Veldhoven K., CueninC., Campanella G., Brennan K., Clavel-Chapelon F., Dossus L., KvaskoffM., Drogan D., Boeing H., Kaaks R., Risch A., Trichopoulos D. i wsp.:Methylome analysis and epigenetic changes associated with menarchealage. PLoS One, 2013; 8: e79391
Google Scholar - 15. Dubeau L.: The cell of origin of ovarian epithelial tumors andthe ovarian surface epithelium dogma: does the emperor have noclothes? Gynecol. Oncol., 1999; 72: 437-442
Google Scholar - 15. Dubeau L.: The cell of origin of ovarian epithelial tumors andthe ovarian surface epithelium dogma: does the emperor have noclothes? Gynecol. Oncol., 1999; 72: 437-442
Google Scholar - 16. Enomoto T., Weghorst C.M., Inoue M., Tanizawa O., Rice J.M.: Krasactivation occurs frequently in mucinous adenocarcinomas andrarely in other common epithelial tumors of the human ovary. Am.J. Pathol., 1991; 139: 777-785
Google Scholar - 16. Enomoto T., Weghorst C.M., Inoue M., Tanizawa O., Rice J.M.: Krasactivation occurs frequently in mucinous adenocarcinomas andrarely in other common epithelial tumors of the human ovary. Am.J. Pathol., 1991; 139: 777-785
Google Scholar - 17. Erickson B.K., Conner M.G., Landen C.N.Jr.: The role of the fallopiantube in the origin of ovarian cancer. Am. J. Obstet. Gynecol.,2013; 209: 409-414
Google Scholar - 17. Erickson B.K., Conner M.G., Landen C.N.Jr.: The role of the fallopiantube in the origin of ovarian cancer. Am. J. Obstet. Gynecol.,2013; 209: 409-414
Google Scholar - 18. Fathalla M.F.: Incessant ovulation – a factor in ovarian neoplasia?Lancet, 1971; 2: 163
Google Scholar - 18. Fathalla M.F.: Incessant ovulation – a factor in ovarian neoplasia?Lancet, 1971; 2: 163
Google Scholar - 19. Francis-Thickpenny K.M., Richardson D.M., van Ee C.C., LoveD.R., Winship I.M., Baguley B.C., Chenevix-Trench G., Shelling A.N.:Analysis of the TGF-β functional pathway in epithelial ovarian carcinoma.Br. J. Cancer, 2001; 85: 687-691
Google Scholar - 19. Francis-Thickpenny K.M., Richardson D.M., van Ee C.C., LoveD.R., Winship I.M., Baguley B.C., Chenevix-Trench G., Shelling A.N.:Analysis of the TGF-β functional pathway in epithelial ovarian carcinoma.Br. J. Cancer, 2001; 85: 687-691
Google Scholar - 20. Gemignani M.L., Schlaerth A.C., Bogomolniy F., Barakat R.R.,Lin O., Soslow R., Venkatraman E., Boyd J.: Role of KRAS and BRAFgene mutations in mucinous ovarian carcinoma. Gynecol. Oncol.,2003; 90: 378-381
Google Scholar - 20. Gemignani M.L., Schlaerth A.C., Bogomolniy F., Barakat R.R.,Lin O., Soslow R., Venkatraman E., Boyd J.: Role of KRAS and BRAFgene mutations in mucinous ovarian carcinoma. Gynecol. Oncol.,2003; 90: 378-381
Google Scholar - 21. George S.H., Shaw P.: BRCA and early events in the developmentof serous ovarian cancer. Front. Oncol., 2014; 4: 5
Google Scholar - 21. George S.H., Shaw P.: BRCA and early events in the developmentof serous ovarian cancer. Front. Oncol., 2014; 4: 5
Google Scholar - 22. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality andPrevalence Worldwide in 2012 http://globocan.iarc.fr/Default.aspx(12.11.2014)
Google Scholar - 22. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality andPrevalence Worldwide in 2012 http://globocan.iarc.fr/Default.aspx(12.11.2014)
Google Scholar - 23. Gotlieb W.H., Amant F., Advani S., Goswami C., Hirte H.,Provencher D., Somani N., Yamada S.D., Tamby J.F., Vergote I.: Intravenousaflibercept for treatment of recurrent symptomatic malignantascites in patients with advanced ovarian cancer: a phase 2,randomised, double-blind, placebo-controlled study. Lancet Oncol.,2012; 13: 154-162
Google Scholar - 23. Gotlieb W.H., Amant F., Advani S., Goswami C., Hirte H.,Provencher D., Somani N., Yamada S.D., Tamby J.F., Vergote I.: Intravenousaflibercept for treatment of recurrent symptomatic malignantascites in patients with advanced ovarian cancer: a phase 2,randomised, double-blind, placebo-controlled study. Lancet Oncol.,2012; 13: 154-162
Google Scholar - 24. Gras E., Catasus L., Arguelles R., Moreno-Bueno G., Palacios J.,Gamallo C., Matias-Guiu X., Prat J.: Microsatellite instability, MLH-1promoter hypermethylation, and frameshift mutations at codingmononucleotide repeat microsatellites in ovarian tumors. Cancer,2001; 92: 2829-2836
Google Scholar - 24. Gras E., Catasus L., Arguelles R., Moreno-Bueno G., Palacios J.,Gamallo C., Matias-Guiu X., Prat J.: Microsatellite instability, MLH-1promoter hypermethylation, and frameshift mutations at codingmononucleotide repeat microsatellites in ovarian tumors. Cancer,2001; 92: 2829-2836
Google Scholar - 25. Ichikawa Y., Nishida M., Suzuki H., Yoshida S., Tsunoda H., KuboT., Uchida K., Miwa M.: Mutations of K-ras protooncogene is associatedwith histological subtypes in human mucinous ovarian tumors.Cancer Res., 1994; 54: 33-35
Google Scholar - 25. Ichikawa Y., Nishida M., Suzuki H., Yoshida S., Tsunoda H., KuboT., Uchida K., Miwa M.: Mutations of K-ras protooncogene is associatedwith histological subtypes in human mucinous ovarian tumors.Cancer Res., 1994; 54: 33-35
Google Scholar - 26. Jones P.M., Drapkin R.: Modeling high-grade serous carcinoma:how converging insights into pathogenesis and genetics are drivingbetter experimental platforms. Front. Oncol., 2013; 3: 217
Google Scholar - 26. Jones P.M., Drapkin R.: Modeling high-grade serous carcinoma:how converging insights into pathogenesis and genetics are drivingbetter experimental platforms. Front. Oncol., 2013; 3: 217
Google Scholar - 27. Jones S., Wang T.L., Shih I.M., Mao T.L., Nakayama K., RodenR., Glas R., Slamon D., Diaz L.A.Jr., Vogelstein B., Kinzler K.W., VelculescuV.E., Papadopoulos N.: Frequent mutations of chromatinremodeling gene ARID1A in ovarian clear cell carcinoma. Science,2010; 330: 228-231
Google Scholar - 27. Jones S., Wang T.L., Shih I.M., Mao T.L., Nakayama K., RodenR., Glas R., Slamon D., Diaz L.A.Jr., Vogelstein B., Kinzler K.W., VelculescuV.E., Papadopoulos N.: Frequent mutations of chromatinremodeling gene ARID1A in ovarian clear cell carcinoma. Science,2010; 330: 228-231
Google Scholar - 28. Karczmarek-Borowska B., Trelińska-Nowosad T., Karolewski K.,Jóźwik P.: Leczenie celowane w raku jajnika – na jakim etapie jeste-śmy? Współczesna Onkologia, 2007; 11: 492-497
Google Scholar - 28. Karczmarek-Borowska B., Trelińska-Nowosad T., Karolewski K.,Jóźwik P.: Leczenie celowane w raku jajnika – na jakim etapie jeste-śmy? Współczesna Onkologia, 2007; 11: 492-497
Google Scholar - 29. Karst A.M., Drapkin R.: Ovarian cancer pathogenesis: a modelin evolution. J. Oncol., 2010; 2010: 932371
Google Scholar - 29. Karst A.M., Drapkin R.: Ovarian cancer pathogenesis: a modelin evolution. J. Oncol., 2010; 2010: 932371
Google Scholar - 30. Kindelberger D.W., Lee Y., Miron A., Hirsch M.S., Feltmate C., MedeirosF., Callahan M.J., Garner E.O., Gordon R.W., Birch C., BerkowitzR.S., Muto M.G., Crum C.P.: Intraepithelial carcinoma of the fimbriaand pelvic serous carcinoma: evidence for a casual relatonship. Am.J. Surg. Pathol., 2007; 31: 161-169
Google Scholar - 30. Kindelberger D.W., Lee Y., Miron A., Hirsch M.S., Feltmate C., MedeirosF., Callahan M.J., Garner E.O., Gordon R.W., Birch C., BerkowitzR.S., Muto M.G., Crum C.P.: Intraepithelial carcinoma of the fimbriaand pelvic serous carcinoma: evidence for a casual relatonship. Am.J. Surg. Pathol., 2007; 31: 161-169
Google Scholar - 31. Kisielewski R., Tołwińska A., Mazurek A., Laudański P.: Inflammationand ovarian cancer – current views. Ginekol. Pol., 2013; 84:293-297
Google Scholar - 31. Kisielewski R., Tołwińska A., Mazurek A., Laudański P.: Inflammationand ovarian cancer – current views. Ginekol. Pol., 2013; 84:293-297
Google Scholar - 32. Kluzek K., Białkowska A., Koczorowska A., Zdzienicka M.Z.: Inhibitorypolimerazy poli(ADP-rybozy) (PARP) w terapii nowotworówz mutacjami BRCA1/2. Postępy Hig. Med. Dośw., 2012; 66: 372-384
Google Scholar - 32. Kluzek K., Białkowska A., Koczorowska A., Zdzienicka M.Z.: Inhibitorypolimerazy poli(ADP-rybozy) (PARP) w terapii nowotworówz mutacjami BRCA1/2. Postępy Hig. Med. Dośw., 2012; 66: 372-384
Google Scholar - 33. Kounelis S., Jones M.W., Papadaki H., Bakker A., Swalsky P., FinkelsteinS.D.: Carcinosarcomas (malignant mixed mullerian tumors)of the female genital tract: comparative molecular analysis of epithelialand mesenchymal components. Hum. Pathol., 1998; 29: 82-87
Google Scholar - 33. Kounelis S., Jones M.W., Papadaki H., Bakker A., Swalsky P., FinkelsteinS.D.: Carcinosarcomas (malignant mixed mullerian tumors)of the female genital tract: comparative molecular analysis of epithelialand mesenchymal components. Hum. Pathol., 1998; 29: 82-87
Google Scholar - 34. Kozak-Pawulska B., Sudoł-Szopińska I., Jakubowski W.: Anatomiaprawidłowa i ultrasonograficzna jajnika, w tym obraz zmianzachodzących w trakcie cyklu jajnikowego. Medycyna Rodzinna,2007; 2: 43-49
Google Scholar - 34. Kozak-Pawulska B., Sudoł-Szopińska I., Jakubowski W.: Anatomiaprawidłowa i ultrasonograficzna jajnika, w tym obraz zmianzachodzących w trakcie cyklu jajnikowego. Medycyna Rodzinna,2007; 2: 43-49
Google Scholar - 35. Kupryjańczyk J., Thor A.D., Beauchamp R., Merritt V., EdgertonS.M., Bell D.A., Yandell D.W.: p53 gene mutations and proteinaccumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA,1993; 90: 4961-4965
Google Scholar - 35. Kupryjańczyk J., Thor A.D., Beauchamp R., Merritt V., EdgertonS.M., Bell D.A., Yandell D.W.: p53 gene mutations and proteinaccumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA,1993; 90: 4961-4965
Google Scholar - 36. Kurman R.J., Shih I.M.: The origin and pathogenesis of epithelialovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol.,2010; 34: 433-443
Google Scholar - 36. Kurman R.J., Shih I.M.: The origin and pathogenesis of epithelialovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol.,2010; 34: 433-443
Google Scholar - 37. Kurman R.J., Shih I.M.: Molecular pathogenesis and extraovarianorigin of epithelial ovarian cancer – shifting the paradigm. Hum.Pathol., 2011; 42: 918-931
Google Scholar - 37. Kurman R.J., Shih I.M.: Molecular pathogenesis and extraovarianorigin of epithelial ovarian cancer – shifting the paradigm. Hum.Pathol., 2011; 42: 918-931
Google Scholar - 38. Kurman R.J., Shih I.M.: Pathogenesis of ovarian cancer: lessonsfrom morphology and molecular biology and their clinical implications.Int. J. Gynecol. Pathol., 2008; 27: 151-160
Google Scholar - 38. Kurman R.J., Shih I.M.: Pathogenesis of ovarian cancer: lessonsfrom morphology and molecular biology and their clinical implications.Int. J. Gynecol. Pathol., 2008; 27: 151-160
Google Scholar - 39. Lalwani N., Prasad S.R., Vikram R., Shanbhogue A.K., HuettnerP.C., Fasih N.: Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics,2011; 31: 625-646
Google Scholar - 39. Lalwani N., Prasad S.R., Vikram R., Shanbhogue A.K., HuettnerP.C., Fasih N.: Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics,2011; 31: 625-646
Google Scholar - 40. Lee Y., Miron A., Drapkin R., Nucci M.R., Medeiros F., SaleemuddinA., Garber J., Birch C., Mou H., Gordon R.W., Cramer D.W., McKeonF.D., Crum C.P.: A candidate precursor to serous carcinoma thatoriginates in the distal fallopian tube. J. Pathol., 2007; 211: 26-35
Google Scholar - 40. Lee Y., Miron A., Drapkin R., Nucci M.R., Medeiros F., SaleemuddinA., Garber J., Birch C., Mou H., Gordon R.W., Cramer D.W., McKeonF.D., Crum C.P.: A candidate precursor to serous carcinoma thatoriginates in the distal fallopian tube. J. Pathol., 2007; 211: 26-35
Google Scholar - 41. Li J., Fadare O., Xiang L., Kong B., Zheng W.: Ovarian serous carcinoma:recent concepts on its origin and carcinogenesis. J. Hematol.Oncol., 2012; 5: 8
Google Scholar - 41. Li J., Fadare O., Xiang L., Kong B., Zheng W.: Ovarian serous carcinoma:recent concepts on its origin and carcinogenesis. J. Hematol.Oncol., 2012; 5: 8
Google Scholar - 42. LifeMap Discovery. Chapter 104. Development of The FemaleGenital System: Ovarian Differentiation. http://discovery.lifemapsc.com/library/review-of-medical-embryology/(13.12.2013)
Google Scholar - 42. LifeMap Discovery. Chapter 104. Development of The FemaleGenital System: Ovarian Differentiation. http://discovery.lifemapsc.com/library/review-of-medical-embryology/(13.12.2013)
Google Scholar - 43. Lisowska K.M.: Profil ekspresji genów w raku jajnika: znaczeniedziedzicznej mutacji genu BRCA1 na tle innych cech molekularnychi klinicznych guza (rozprawa habilitacyjna). J. Oncol., 2007; 57 (Suppl. 8): 7-97
Google Scholar - 43. Lisowska K.M.: Profil ekspresji genów w raku jajnika: znaczeniedziedzicznej mutacji genu BRCA1 na tle innych cech molekularnychi klinicznych guza (rozprawa habilitacyjna). J. Oncol., 2007; 57 (Suppl. 8): 7-97
Google Scholar - 44. Lisowska K.M., Dudaladava V., Jarzab M., Huzarski T., ChmielikE., Stobiecka E., Lubinski J., Jarzab B.: BRCA1-related gene signaturein breast cancer: the role of ER status and molecular type. Front.Biosci., 2011; 3: 125-136
Google Scholar - 44. Lisowska K.M., Dudaladava V., Jarzab M., Huzarski T., ChmielikE., Stobiecka E., Lubinski J., Jarzab B.: BRCA1-related gene signaturein breast cancer: the role of ER status and molecular type. Front.Biosci., 2011; 3: 125-136
Google Scholar - 45. Lisowska K.M., Olbryt M., Dudaladava V., Pamuła-Piłat J., KujawaK., Grzybowska E., Jarząb M., Student S., Rzepecka I.K., JarząbB., Kupryjańczyk J.: Gene expression analysis in ovarian cancer -faults and hints from DNA microarray study. Front. Oncol., 2014; 4: 6
Google Scholar - 45. Lisowska K.M., Olbryt M., Dudaladava V., Pamuła-Piłat J., KujawaK., Grzybowska E., Jarząb M., Student S., Rzepecka I.K., JarząbB., Kupryjańczyk J.: Gene expression analysis in ovarian cancer -faults and hints from DNA microarray study. Front. Oncol., 2014; 4: 6
Google Scholar - 46. Marquez R.T., Baggerly K.A., Patterson A.P., Liu J., Broaddus R.,Frumovitz M., Atkinson E.N., Smith D.I., Hartmann L., Fishman D.,Berchuck A., Whitaker R., Gershenson D.M., Mills G.B., Bast R.C.Jr., LuK.H.: Patterns of gene expression in different histotypes of epithelialovarian cancer correlate with those in normal fallopian tube, endometrium,and colon. Clin. Cancer Res., 2005; 11: 6116-6126
Google Scholar - 46. Marquez R.T., Baggerly K.A., Patterson A.P., Liu J., Broaddus R.,Frumovitz M., Atkinson E.N., Smith D.I., Hartmann L., Fishman D.,Berchuck A., Whitaker R., Gershenson D.M., Mills G.B., Bast R.C.Jr., LuK.H.: Patterns of gene expression in different histotypes of epithelialovarian cancer correlate with those in normal fallopian tube, endometrium,and colon. Clin. Cancer Res., 2005; 11: 6116-6126
Google Scholar - 47. McAlpine J.N., Wiegand K.C., Vang R., Ronnett B.M., Adamiak A.,Köbel M., Kalloger S.E., Swenerton K.D., Huntsman D.G., Gilks C.B.,Miller D.M.: HER2 overexpression and amplification is present ina subset of ovarian mucinous carcinomas and can be targeted withtrastuzumab therapy. BMC Cancer, 2009; 9: 433
Google Scholar - 47. McAlpine J.N., Wiegand K.C., Vang R., Ronnett B.M., Adamiak A.,Köbel M., Kalloger S.E., Swenerton K.D., Huntsman D.G., Gilks C.B.,Miller D.M.: HER2 overexpression and amplification is present ina subset of ovarian mucinous carcinomas and can be targeted withtrastuzumab therapy. BMC Cancer, 2009; 9: 433
Google Scholar - 48. McCluggage W.G.: Morphological subtypes of ovarian carcinoma:a review with emphasis on new developments and pathogenesis.Pathology, 2011; 43: 420-432
Google Scholar - 48. McCluggage W.G.: Morphological subtypes of ovarian carcinoma:a review with emphasis on new developments and pathogenesis.Pathology, 2011; 43: 420-432
Google Scholar - 49. Nowak-Markwitz E., Spaczyński M.: Rak jajnika – nowe pojrzeniena pochodzenie i histogenezę Ginekol. Pol., 2012; 83: 454-457
Google Scholar - 49. Nowak-Markwitz E., Spaczyński M.: Rak jajnika – nowe pojrzeniena pochodzenie i histogenezę Ginekol. Pol., 2012; 83: 454-457
Google Scholar - 50. O’Neill C.J., McBride H.A., Connolly L.E., Deavers M.T., MalpicaA., McCluggage W.G.: High-grade ovarian serous carcinoma exhibitssignificantly higher p16 expression than low-grade serous carcinomaand serous borderline tumour. Histopathology, 2007; 50: 773-779
Google Scholar - 50. O’Neill C.J., McBride H.A., Connolly L.E., Deavers M.T., MalpicaA., McCluggage W.G.: High-grade ovarian serous carcinoma exhibitssignificantly higher p16 expression than low-grade serous carcinomaand serous borderline tumour. Histopathology, 2007; 50: 773-779
Google Scholar - 51. Obata K., Morland S.J., Watson R.H., Hitchcock A., ChenevixTrenchG., Thomas E.J., Campbell I.G.: Frequent PTEN/MMAC mutationsin endometrioid but not serous or mucinous epithelial ovariantumors. Cancer Res., 1998; 58: 2095-2097
Google Scholar - 51. Obata K., Morland S.J., Watson R.H., Hitchcock A., ChenevixTrenchG., Thomas E.J., Campbell I.G.: Frequent PTEN/MMAC mutationsin endometrioid but not serous or mucinous epithelial ovariantumors. Cancer Res., 1998; 58: 2095-2097
Google Scholar - 52. Ovarian Cancer 2014 Report. Food, Nutrition, Physical Activity, andthe Prevention of Ovarian Cancer. http://www.aicr.org/continuousupdate-project/reports/ovarian-cancer-2014-report.pdf(12.11.2014)
Google Scholar - 52. Ovarian Cancer 2014 Report. Food, Nutrition, Physical Activity, andthe Prevention of Ovarian Cancer. http://www.aicr.org/continuousupdate-project/reports/ovarian-cancer-2014-report.pdf(12.11.2014)
Google Scholar - 53. Ovarian Cancer Incidence: Current and Comprehensive Statistics.http://cdn.intechopen.com/pdfs/28502/InTech-Ovarian_cancer_incidence_current_and_comprehensive_statistics.pdf(12.11.2014)
Google Scholar - 53. Ovarian Cancer Incidence: Current and Comprehensive Statistics.http://cdn.intechopen.com/pdfs/28502/InTech-Ovarian_cancer_incidence_current_and_comprehensive_statistics.pdf(12.11.2014)
Google Scholar - 54. Piek J.M., van Diest P.J., Zweemer R.P., Kenemans P., VerheijenR.H.: Tubal ligation and risk of ovarian cancer. Lancet, 2001; 358: 844
Google Scholar - 54. Piek J.M., van Diest P.J., Zweemer R.P., Kenemans P., VerheijenR.H.: Tubal ligation and risk of ovarian cancer. Lancet, 2001; 358: 844
Google Scholar - 55. Purdie D.M., Bain C.J., Siskind V., Russell P., Hacker N.F., WardB.G., Quinn M.A., Green A.C.: Hormone replacement therapy and riskof epithelial ovarian cancer. Br. J. Cancer, 1999; 81: 559-563
Google Scholar - 55. Purdie D.M., Bain C.J., Siskind V., Russell P., Hacker N.F., WardB.G., Quinn M.A., Green A.C.: Hormone replacement therapy and riskof epithelial ovarian cancer. Br. J. Cancer, 1999; 81: 559-563
Google Scholar - 56. Rosenblatt K.A., Thomas D.B.: Reduced risk of ovarian cancerin women with a tubal ligation or hysterectomy. The World HealthOrganization Collaborative Study of Neoplasia and Steroid Contraceptives.Cancer Epidemiol. Biomarkers Prev., 1996; 5: 933-935
Google Scholar - 56. Rosenblatt K.A., Thomas D.B.: Reduced risk of ovarian cancerin women with a tubal ligation or hysterectomy. The World HealthOrganization Collaborative Study of Neoplasia and Steroid Contraceptives.Cancer Epidemiol. Biomarkers Prev., 1996; 5: 933-935
Google Scholar - 57. Ruf P., Kluge M., Jäger M., Burges A., Volovat C., Heiss M.M.,Hess J., Wimberger P., Brandt B., Lindhofer H.: Pharmacokinetics,immunogenicity and bioactivity of the therapeutic antibody catumaxomabintraperitoneally administered to cancer patients. Br. J.Clin. Pharmacol., 2010; 69: 617-625
Google Scholar - 57. Ruf P., Kluge M., Jäger M., Burges A., Volovat C., Heiss M.M.,Hess J., Wimberger P., Brandt B., Lindhofer H.: Pharmacokinetics,immunogenicity and bioactivity of the therapeutic antibody catumaxomabintraperitoneally administered to cancer patients. Br. J.Clin. Pharmacol., 2010; 69: 617-625
Google Scholar - 58. Sato N., Tsunoda H., Nishida M., Morishita Y., Takimoto Y., KuboT., Noguchi M.: Loss of heterozygosity on 10q23.3 and mutation ofthe tumor suppressor gene PTEN in benign endometrial cyst of theovary: possible sequence progression from benign endometrial cystto endometrioid carcinoma and clear cell carcinoma of the ovary.Cancer Res., 2000; 60: 7052-7056
Google Scholar - 58. Sato N., Tsunoda H., Nishida M., Morishita Y., Takimoto Y., KuboT., Noguchi M.: Loss of heterozygosity on 10q23.3 and mutation ofthe tumor suppressor gene PTEN in benign endometrial cyst of theovary: possible sequence progression from benign endometrial cystto endometrioid carcinoma and clear cell carcinoma of the ovary.Cancer Res., 2000; 60: 7052-7056
Google Scholar - 59. Seidman J.D., Khedmati F.: Exploring the histogenesis of ovarianmucinous and transitional cell (Brenner) neoplasms and theirrelationship with Walthard cell nests: a study of 120 tumors. Arch.Pathol. Lab. Med., 2008; 132: 1753-1760
Google Scholar - 59. Seidman J.D., Khedmati F.: Exploring the histogenesis of ovarianmucinous and transitional cell (Brenner) neoplasms and theirrelationship with Walthard cell nests: a study of 120 tumors. Arch.Pathol. Lab. Med., 2008; 132: 1753-1760
Google Scholar - 60. Senturk E., Cohen S., Dottino P.R., Martignetti J.A.: A critical reappraisalof BRCA1 methylation studies in ovarian cancer. Gynecol.Oncol., 2010; 119: 376-383
Google Scholar - 60. Senturk E., Cohen S., Dottino P.R., Martignetti J.A.: A critical reappraisalof BRCA1 methylation studies in ovarian cancer. Gynecol.Oncol., 2010; 119: 376-383
Google Scholar - 61. Shih I.M., Kurman R.J.: Ovarian tumorigenesis: a proposed modelbased on morphological and molecular genetic analysis. Am. J.Pathol., 2004; 164: 1511-1518
Google Scholar - 61. Shih I.M., Kurman R.J.: Ovarian tumorigenesis: a proposed modelbased on morphological and molecular genetic analysis. Am. J.Pathol., 2004; 164: 1511-1518
Google Scholar - 62. Sieben N.L., Macropoulos P., Roemen G.M., Kolkman-Uljee S.M.,Jan Fleuren G., Houmadi R., Diss T., Warren B., Al Adnani M., DeGoeij A.P., Krausz T., Flanagan A.M.: In ovarian neoplasms, BRAF, butnot KRAS, mutations are restricted to low-grade serous tumours. J.Pathol., 2004; 202: 336-340
Google Scholar - 62. Sieben N.L., Macropoulos P., Roemen G.M., Kolkman-Uljee S.M.,Jan Fleuren G., Houmadi R., Diss T., Warren B., Al Adnani M., DeGoeij A.P., Krausz T., Flanagan A.M.: In ovarian neoplasms, BRAF, butnot KRAS, mutations are restricted to low-grade serous tumours. J.Pathol., 2004; 202: 336-340
Google Scholar - 63. Singer G., Oldt R.3rd, Cohen Y., Wang B.G., Sidransky D., KurmanR.J., Shih I.M.: Mutations in BRAF and KRAS characterize thedevelopment of low-grade ovarian serous carcinoma. J. Natl. CancerInst., 2003; 95: 484-486
Google Scholar - 63. Singer G., Oldt R.3rd, Cohen Y., Wang B.G., Sidransky D., KurmanR.J., Shih I.M.: Mutations in BRAF and KRAS characterize thedevelopment of low-grade ovarian serous carcinoma. J. Natl. CancerInst., 2003; 95: 484-486
Google Scholar - 64. Terry K.L., Titus-Ernstoff L., McKolanis J.R., Welch W.R., Finn O.J.,Cramer D.W.: Incessant ovulation, mucin 1 immunity, and risk forovarian cancer. Cancer Epidemiol. Biomarkers Prev., 2007; 16: 30-35
Google Scholar - 64. Terry K.L., Titus-Ernstoff L., McKolanis J.R., Welch W.R., Finn O.J.,Cramer D.W.: Incessant ovulation, mucin 1 immunity, and risk forovarian cancer. Cancer Epidemiol. Biomarkers Prev., 2007; 16: 30-35
Google Scholar - 65. Vaughan S., Coward J.I., Bast R.C.Jr., Berchuck A., Berek J.S.,Brenton J.D., Coukos G., Crum C.C., Drapkin R., EtemadmoghadamD., Friedlander M., Gabra H., Kaye S.B., Lord C.J., Lengyel E. i wsp.:Rethinking ovarian cancer: recommendations for improving outcomes.Nat. Rev. Cancer, 2012; 11: 719-725
Google Scholar - 65. Vaughan S., Coward J.I., Bast R.C.Jr., Berchuck A., Berek J.S.,Brenton J.D., Coukos G., Crum C.C., Drapkin R., EtemadmoghadamD., Friedlander M., Gabra H., Kaye S.B., Lord C.J., Lengyel E. i wsp.:Rethinking ovarian cancer: recommendations for improving outcomes.Nat. Rev. Cancer, 2012; 11: 719-725
Google Scholar - 66. Walters C.L., Arend R.C., Armstrong D.K., Naumann R.W., AlvarezR.D.: Folate and folate receptor alpha antagonists mechanism of actionin ovarian cancer. Gynecol. Oncol., 2013; 131: 493-498
Google Scholar - 66. Walters C.L., Arend R.C., Armstrong D.K., Naumann R.W., AlvarezR.D.: Folate and folate receptor alpha antagonists mechanism of actionin ovarian cancer. Gynecol. Oncol., 2013; 131: 493-498
Google Scholar - 67. Wells T.S. Diseases of the ovaries: their diagnosis and treatment.:J. & A. Churchill, London, 1872
Google Scholar - 67. Wells T.S. Diseases of the ovaries: their diagnosis and treatment.:J. & A. Churchill, London, 1872
Google Scholar - 68. Wojnarowicz P.M., Oros K.K., Quinn M.C., Arcand S.L., GambaroK., Madore J., Birch A.H., de Ladurantaye M., Rahimi K., ProvencherD.M., Mes-Masson A.M., Greenwood C.M., Tonin P.N.: The genomiclandscape of TP53 and p53 annotated high grade ovarian serous carcinomasfrom a defined founder population associated with patientoutcome. PLoS One, 2012; 7: e45484
Google Scholar - 68. Wojnarowicz P.M., Oros K.K., Quinn M.C., Arcand S.L., GambaroK., Madore J., Birch A.H., de Ladurantaye M., Rahimi K., ProvencherD.M., Mes-Masson A.M., Greenwood C.M., Tonin P.N.: The genomiclandscape of TP53 and p53 annotated high grade ovarian serous carcinomasfrom a defined founder population associated with patientoutcome. PLoS One, 2012; 7: e45484
Google Scholar - 69. Worley M.J., Welch W.R., Berkowitz R.S., Ng S.W.: Endometriosisassociatedovarian cancer: a review of pathogenesis. Int. J. Mol. Sci.,2013; 14: 5367-5379
Google Scholar - 69. Worley M.J., Welch W.R., Berkowitz R.S., Ng S.W.: Endometriosisassociatedovarian cancer: a review of pathogenesis. Int. J. Mol. Sci.,2013; 14: 5367-5379
Google Scholar - 70. Wu R., Zhai Y., Fearon E.R., Cho K.R.: Diverse mechanisms of Bcateninderegulation in ovarian endometrioid adenocarcinomas.Cancer Res., 2001; 61: 8247-8255
Google Scholar - 70. Wu R., Zhai Y., Fearon E.R., Cho K.R.: Diverse mechanisms of Bcateninderegulation in ovarian endometrioid adenocarcinomas.Cancer Res., 2001; 61: 8247-8255
Google Scholar - 71. Wybrane zagadnienia współczesnej onkologii. Rozdział 12.http://www.onkoedu.viamedica.pl/zeszyty/article/8024/chapter_12.html(07.01.2015)
Google Scholar - 71. Wybrane zagadnienia współczesnej onkologii. Rozdział 12.http://www.onkoedu.viamedica.pl/zeszyty/article/8024/chapter_12.html(07.01.2015)
Google Scholar - 72. Wybrane zagadnienia współczesnej onkologii. Rozdział 13http://www.onkoedu.viamedica.pl/zeszyty/article/8024/chapter_13.html(07.01.2015)
Google Scholar - 72. Wybrane zagadnienia współczesnej onkologii. Rozdział 13http://www.onkoedu.viamedica.pl/zeszyty/article/8024/chapter_13.html(07.01.2015)
Google Scholar